Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report
| Autor: | F. Rocher, Stéphanie Baillif, N. Tieulie, Arnaud Martel, M. Loschi, T. Ferrete, V. Elmaleh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Lifitegrast Phenylalanine medicine.medical_treatment Graft vs Host Disease Amputation Surgical 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Humans Medical history Sulfones Evisceration (ophthalmology) Aged business.industry Eye drop Corneal perforation medicine.disease Dermatology eye diseases Transplantation Ophthalmology Graft-versus-host disease chemistry 030221 ophthalmology & optometry Dry Eye Syndromes Complication business |
| Zdroj: | Journal Français d'Ophtalmologie. 44:652-657 |
| ISSN: | 0181-5512 |
| DOI: | 10.1016/j.jfo.2020.12.004 |
| Popis: | Graft-versus-host disease (GVHD) is a common complication in patients undergoing allogeneic stem cell transplantation for acute myeloblastic leukemia that could be very difficult to treat. Lifitegrast 5% (Xiidra@, Novartis), a new immunosuppressive eye drop, was recently approved by the FDA for the treatment of severe dry eye and is currently under review by the European Medicines Agency. In France, lifitegrast has been approved by the French authorities for temporary use in refractory dry eye syndrome resistant to tear substitutes and topical cyclosporine. To date, serious complications have been reported only exceptionally. In this article, we report the case of a 65-year-old patient with a medical history of acute myeloid leukemia (AML) diagnosed in 2015 who received a first matched related donor transplant. In 2019, this patient developed chronic GVH involving the skin, oral mucosa and eye. Despite taking topical and systemic medications for 3 months, the patient did not report relief of ocular symptoms. Therefore, lifitegrast was prescribed. To our knowledge, we report the first case of corneal perforation in which evisceration was required following treatment with topical lifitegrast for chronic GVH. In the case presented here, it can be assumed that the underlying mechanisms leading to corneal perforation are multifactorial. Using drug accountability criteria, lifitegrast appears to be strongly associated with the development of bacterial keratitis and corneal perforation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|